替格瑞洛对ACS患者血清hs-CRP及血浆Hcy水平的影响  

Effects of ticagrelor on serum hs-CRP and plasma Hcy levels in patients with ACS

作　　者：曹佐锋[1] 何苗[1] CAO Zuofeng;HE Miao(Department of Cardiology,the First Affiliated Hospital of Gannan Medical College,Ganzhou,Jiangxi,341000,China)

机构地区：[1]赣南医学院第一附属医院心内科,江西赣州341000

出　　处：《当代医学》2021年第23期8-10,共3页Contemporary Medicine

基　　金：赣州市指导性科技计划项目(GZ2017ZSF086)。

摘　　要：目的探讨替格瑞洛对急性冠脉综合征(ACS)患者血清高敏C-反应蛋白(hs-CRP)及血浆同型半胱氨酸(Hcy)水平的影响。方法选取2018年1月至2019年12月本院收治的88例急性冠脉综合征患者,根据治疗方法的不同分为对照组和观察组,每组44例。对照组采用阿司匹林+氯吡格雷治疗,观察组采用阿司匹林+替格瑞洛治疗。比较两组临床疗效、血清指标、心功能指标、不良反应发生情况。结果治疗后,观察组治疗总有效率、左室射血分数(LVEF)、舒张晚期二尖瓣血流速度峰值(E/A)水平高于对照组,hs-CRP、Hcy、左室收缩末期内径(LVEDs)、左室舒张末期内径(LVEDd)水平、不良反应发生率均低于对照组,差异有统计学意义(P<0.05)。结论替格瑞洛治疗ACS效果显著,有利于减轻患者炎性反应,减少不良心血管事件,值得临床推广应用。Objective To investigate the effect of ticagrelor on serum high-sensitivity C-reactive protein(hs-CRP)and plasma homocysteine(Hcy)levels in patients with acute coronary syndrome(ACS).Methods 88 patients with acute coronary syndrome(ACS)admitted to our hospital from January 2018 to December 2019 were selected and they were divided into control group and observation group according to different treatment methods,with 44 cases in each group.The control group was treated with aspirin+clopidogrel,and the observation group was treated with aspirin+ticagrelor.The clinical efficacy,serum indexes,cardiac function indexes,and occurrence of adverse reactions were compared between the two groups.Results After treatment,the total effective rate,left ventricular ejection fraction(LVEF),and late diastolic mitral valve blood flow peak(E/A)levels of the observation group were higher than those of the control group,and hs-CRP,Hcy,and left ventricular end-systolic diameter(LVEDs),left ventricular end diastolic diameter(LVEDd)levels,and the incidence of adverse reactions were lower than those of the control group,the difference was statistically significant(P<0.05).Conclusion Ticagrelor has ideal effect in the treatment of ACS,which is beneficial to reduce the inflammatory reaction of patients and reduce the adverse cardiovascular events.It is worthy of clinical application.

关 键 词：替格瑞洛 急性冠脉综合征 高敏C反应蛋白 同型半胱氨酸 

分 类 号：R541.4[医药卫生—心血管疾病]